Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estramustine a radio sensitising agent.

M Edgren1, B Lennernäs

  • 1Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.

Anticancer Research
|August 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparative analysis of radiobiological models for cell surviving fractions at high doses.

Technology in cancer research & treatment·2012
Same author

A comparison of positron emission tomography (pet) utilizing C-11 methionine and computerized-tomography in the diagnosis of renal-cell adenocarcinoma.

Oncology reports·2011
Same author

Positron emission tomography utilizing C-11 5-hydroxytryptophan, plasma biochemistry and neuroendocrine immunohistochemistry of metastatic renal-cell carcinoma.

Oncology reports·2011
Same author

The use of artificial-intelligence neural networks in the evaluation of treatment plans for external-beam radiotherapy.

Oncology reports·2011
Same author

Radiation-dose dependence of the enhancement of DNA-damage in cells treated with the hypoxic radiosensitizer ak-2123, a 3-nitrotriazole derivative.

International journal of oncology·2011
Same author

Adrenocortical carcinoma - a clinical and immunohistochemical study.

International journal of oncology·2011
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Estramustine shows potential as a radiosensitizing agent for renal cell carcinoma (RCC). Pretreatment with estramustine enhanced the effects of radiation, arresting cancer cell growth and suggesting a new treatment approach for advanced RCC.

Area of Science:

  • Oncology
  • Radiotherapy
  • Pharmacology

Background:

  • Human renal cell cancer (RCC) cell lines A498 and CAKI-2 exhibit significant resistance to external beam irradiation.
  • Estramustine is a chemotherapy drug with potential anticancer properties.

Purpose of the Study:

  • To investigate the radiosensitizing potential of estramustine on human renal cell cancer cell lines.
  • To evaluate the effect of estramustine combined with external beam irradiation on cancer cell growth.

Main Methods:

  • In vitro experiments utilizing Bürker chamber technique.
  • Exposure of A498 and CAKI-2 cell lines to external beam irradiation.
  • Pretreatment of cell cultures with estramustine prior to irradiation.

Main Results:

Related Experiment Videos

  • Both A498 and CAKI-2 cell lines demonstrated marked resistance to external beam irradiation alone.
  • Pretreatment with estramustine followed by irradiation resulted in significant arrest of cell growth in both cell lines.
  • Estramustine demonstrated radiosensitizing effects on the tested renal cell cancer lines.

Conclusions:

  • Estramustine acts as a radiosensitizing agent in human renal cell cancer cell lines.
  • The combination of estramustine and radiation may offer a novel therapeutic strategy for advanced renal cell carcinoma (RCC).
  • Further research is warranted to explore estramustine's clinical application in RCC management.